A031901: Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

About this Study

The purpose of this study is compare survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment wtih immune checkpoint inhibitors.

Sponsor Protocol ID:A031901
IRB Number:2020-0365
Actively Enrolling
Interventional
Phase 3
June 30, 2022
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Histologically or cytologically confirmed urothelial carcinoma (UC) with predominately transitional-cell features
  • Locally advanced or metastatic disease prior to starting immune checkpoint blockade
  • Tumor site:  Bladder, renal pelvis, ureter, urethra, or prostate
  • Must have received at least one cycle of current active treatment with standard of care (SOC) approved PD-1/L1 immune checkpoint inhibitor (CI) containing therapy for locally advance or metastatic UC

Exclusion Criteria
  • History of tuberculosis, active hepatitis B or C, or uncontrolled HIV
  • History of allogeneic organ transplant
  • No current immunosuppressive medication exceeding 10 mg/day of prednisone or it equivalent
  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease for greater than or equal to 2 years.
  • Female patient who are pregnant or nursing

Categories Click category to view its trials.
Cancer
Participating Locations
Center for Integrative Health - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials